摘要
目的:探讨晚期胃癌癌组织中切除修复交叉互补基因1(excision repair cross-complementing gene 1,ERCC1)和乳腺癌易感基因l(breast cancer susceptibility gene 1,BRCA1)的表达状况及其与患者临床病理特征、铂类方案化疗疗效及预后之间的关系。方法:采用免疫组化方法检测晚期胃癌癌组织中ERCC1和BRCA1蛋白的表达状况。结果:晚期胃癌癌组织中ERCC1和BRCA1蛋白表达阳性率分别为28.9%和19.0%。ERCC1和BRCA1蛋白的表达与患者的年龄、性别、PS评分及肿瘤分化程度均无关(P>0.05),胃癌癌组织中ERCC1蛋白表达与BRCA1蛋白表达呈正相关(r=0.248,P=0.006)。ERCC1和BRCA1蛋白表达阴性患者铂类方案化疗有效率高于表达阳性患者(P<0.05)。ERCC1和BRCA1蛋白表达阴性患者化疗后,中位生存期高于表达阳性患者(P<0.05)。COX回归模型分析结果显示ERCC1和BRCA1蛋白的表达状态及肿瘤分化程度是影响胃癌预后的独立因素。结论:晚期胃癌ERCC1和BRCA1蛋白的表达状态可作为化疗方案的选择及预后判断的依据。
Objective：To study the expressions of ERCC1 and BRCA1 in advanced gastric cancer and their correlation with clinicopathological features,efficacy of platinum chemotherapy and prognosis.Methods：Expressions of ERCC1 and BRCA1 proteins in the tissues of advanced gastric cancer were measured by immunohistochemistry.Results：The positive rate of ERCC1 and BRCA1 proteins was 28.9％ and 19.0％ respectively.The expressions of ERCC1 and BRCA1 proteins were not associated with the patient＇s gender,age,PS score and differentiation degree （P ＞ 0.05）.The positive expression of ERCC1 protein had a significantly positive correlation with BRCA1 protein in advanced gastric cancer（r =0.248,P =0.006）.The response rate of chemotherapy in ERCC1 and BRCA1 proteins negative patients was significantly higher than the rate in ERCC1 and BRCA1 positive patients（P ＜ 0.05）.Compared with ERCC1 and BRCA1 positive patients,ERCC1 and BRCA1 negative patients had longer median survival time with statistical difference （P ＜ 0.05）.COX multivariate analysis confirmed that the status of ERCC1 and BRCA1 proteins expressions and differentiation degree were independently correlated with prognosis in advanced gastric cancer.Conclusion：Expressions of ERCC1 and BRCA1 proteins might be useful in the choice of chemotherapy regimens and evaluation of prognosis for patients with advanced gastric cancer.
出处
《现代肿瘤医学》
CAS
2013年第11期2525-2528,共4页
Journal of Modern Oncology
